Other Therapeutic Areas

ILD Disease Process

Interstitial lung diseases (ILDs) encompass a large group of chronic lung conditions that affect the respiratory bronchioles, alveolar walls, and alveolar spaces. These diseases are characterized by progressive scarring (interstitial lung abnormaliites, fibrosis) of lung tissue which can lead to severe respiratory dysfunction.

VIDA’s comprehensive portfolio of quantitative imaging biomarkers for ILD & Idiopathic Pulmonary Fibrosis (IPF) aim to precisely measure physiological changes associated with these diseases, including tissue remodeling (e.g., fibrosis), vascular remodeling, airway remodeling and functional impairment. VIDA’s imaging biomarkers complement traditional non-imaging endpoint measures (e.g., spirometry).

Source: L Plantier, et al. “Physiology of the Lung in Idiopathic Pulmonary Fibrosis.” ERS Review 27, no. 147 (March 31, 2018).

VIDA’s Comprehensive Portfolio of ILD Imaging Biomarkers

Given the wide spectrum of Interstitial lung diseases (ILDs) and their complex pathophysiology, it is often useful for drug developers to evaluate a multifaceted set of imaging biomarkers. VIDA offers 30+ imaging biomarkers that are relevant to ILD/IPF. To learn about this full suite of ILD biomarkers, view our white paper.

Fibrosis Quantification

Fibrosis quantification, based on CT imaging, has grown to be the most common quantitative imaging biomarker in ILD therapeutic clinical trials. Approximately 50% of active, industry-funded, interventional ILD/IPF trials now include fibrosis quantification as a primary or secondary endpoint.

DTA Fibrosis Score

Data-driven Texture Analysis (DTA) Fibrosis Score, licensed from National Jewish Health, quantifies the % of lung volume (and mass) classified as fibrotic. Fibrosis is identified based on hallmark radiologic features, including reticulation, honeycombing, and traction bronchiectasis.

• DTA Fibrosis Score is exceptionally well validated, with an established minimal clinically important difference (MCID) among IPF cohorts of 3.4% (source)
• DTA Fibrosis Score is robust and repeatable across a broad range of ILD populations, with intraclass correlation coefficients of 0.78-0.91. (source)

Xenon MRI for ILD

In parnership with Polarean, VIDA offers innovative Xenon 129 MRI biomarkers. These biomarkers uniquely measure functional impact and therapeutic impact for ILDs.

Mass-Based Tissue Scoring

VIDA has validated a novel mass-based ILD and fibrosis scoring methodology to complement traditional volume-based quantitative scores. This new mass-based tissue quantification, presented at ATS 2024 (source) , demonstrates an improvement in correlations between normal lung mass and non-imaging clinical assessments (FVC, FEV1 and more) compared to volume-based measures. In addition to tighter clinical correlations, the mass-based approach has a major advantage:

Mass is less susceptible to patients’ inspiration efforts. Inspired air volume is dependent on effort and has a significant impact on volume-based quantification, whereas lung mass is mostly consistent across the breath cycle.

In light of these results and advantages, VIDA now provides both volume and mass-based tissue quantification scores for ILD trials.

Novel Visualizations for ILDs

VIDA’s proprietary visualizations complement quantitative measures, providing compelling visual evidence of anatomical changes and therapeutic response. Topographic Multi-Planar Reformat (tMPR) and Subpleura View are two examples.

Data Quality

Biomarker Reliability

Reliability in quantitative CT (QCT) is determined by the consistency (or repeatability) of a measure. QCT measurement consistency (test/re-test) for 38 of VIDA’s digital imaging biomarkers was recently published in the American Journal of Respiratory and Critical Care Medicine. (4) While the cohort was a COPD cohort, many of the biomarkers also apply to ILD/IPF subjects. This important study showed high repeatability and reliability for QCT measures and revealed the importance of high-quality data and performing quality control (QC), which improved repeatability and reliability.

Modern Trial Imaging Management

Not all quantitative imaging data is equal.

To optimize data quality and streamline operational ease, VIDA provides a full range of trial imaging management services, built upon 20+ years of experience. These services are enabled by the VIDA Intelligence Platform, a modern AI-powered trial imaging system.

Since introduction of the innovative platform in early 2022:

*Among trials where imaging metrics are the primary endpoint.

More Resources

If you are interested to learn more about Quantitative Imaging Biomarkers for ILD/IPF, or our trial imaging services, we’d love to speak with you.

Send us a message here.

If addition, please enjoy the following programs and resources related to ILD/IPF:

ILD Studies Utilizing VIDA’s Precision Imaging